(Q36411099)

14 August 2017

1 reference

title

Statins: another class of antihypertensive agents? (English)

1 reference

14 August 2017

author

Evangelos N Liberopoulos

0 references

author name string

Milionis HJ

1

1 reference

14 August 2017

Liberopoulos EN

2

1 reference

14 August 2017

Achimastos A

3

1 reference

14 August 2017

Elisaf MS

4

1 reference

14 August 2017

Mikhailidis DP

5

1 reference

14 August 2017

publication date

1 May 2006

1 reference

Journal of Human Hypertension

14 August 2017

published in

1 reference

14 August 2017

volume

20

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

320-335

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1002001

14 August 2017

exact match

0 references

cites work

AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The impact of JNC-VI guidelines on treatment recommendations in the US population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Hyperlipidaemia, hypertension, and coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Prevention and treatment of the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Statins and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

LDL cholesterol and global risk stratification in referred hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Dyslipidemia and the risk of incident hypertension in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Reversibility of the effects on local circulation of high lipid concentrations in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Obesity hypertension is related more to insulin's fatty acid than glucose action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Hyperinsulinemia and dyslipidemia in non-obese, normotensive offspring of hypertensive parents in northern India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The pressor response to acute hyperlipidemia is enhanced in lean normotensive offspring of hypertensive parents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effects of cholesterol-lowering therapy on pressor hyperreactivity to stress in hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Current Status of Lipid Management of Hypertensive Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Quantitative trait loci influencing cholesterol and phospholipid phenotypes map to chromosomes that contain genes regulating blood pressure in the spontaneously hypertensive rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Lipid lowering: another method of reducing blood pressure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Endothelial nitric oxide synthase gene variant modulates the relationship between serum cholesterol levels and blood pressure in the general population: new evidence for a direct effect of lipids in arterial blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

A review of the lipid-related effects of fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effect of lovastatin on cerebral circulation in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effects of lipid-lowering agents in the Dahl salt-sensitive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Statins and blood pressure regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Statins and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Does lowering of cholesterol levels influence functional properties of large arteries?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Long-term effects of statins on arterial pressure and stiffness of hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Endothelium-dependent effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Aortic pulse wave velocity as a marker of cardiovascular disease in subjects over 70 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Rapid Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition on Coronary Endothelial Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Endothelin: potential role in hypertension and vascular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Membrane cholesterol content modulates activation of volume-regulated anion current in bovine endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

3-Hydroxy-3-methyl glutaryl coenzyme A reductase inhibition modulates vasopressin-stimulated Ca2+ responses in rat A10 vascular smooth muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Diagnosis and management of the metabolic syndrome in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The effects of antihypertensive therapy on haemostatic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Enhanced reduction of atherosclerosis in hamsters treated with pravastatin and captopril: ACE in atheromas provides cellular targets for captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Uric acid levels and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Preventing cardiovascular disease in hypertension: effects of lowering blood pressure and cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Concomitant risk factors in hypertensives: a survey of risk factors for cardiovascular disease amongst hypertensives in English general practices

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Lovastatin prevents development of hypertension in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Simvastatin in the treatment of hypercholesterolaemia in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Influence of hypercholesterolemia on adrenal steroid metabolism and electrolyte balance in spontaneously hypertensive rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Altered contractile and ion channel function in rabbit portal vein with dietary atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

The J-shaped relationship between coronary heart disease and achieved blood pressure level in treated hypertension: further analyses of 12 years of follow-up of treated hypertensives in the Primary Prevention Trial in Gothenburg, Sweden.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Antihypertensive therapy in dyslipidemic men. Effects on coronary heart disease incidence and total mortality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Individual blood pressure responses to changes in salt intake: results from the DASH-Sodium trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

The effect of cholesterol-lowering treatment on renal function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002001

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1002001

1 reference

14 August 2017

1 reference